Erratum to “Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo” [Osteoarthritis Cartilage 12 (2004) 269–276]

Abstract

The publisher regrets that in the above article the fourth author's name was spelt incorrectly. It is now represented correctly above as Florent de Vathaire.

Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan

“…Only a few medications have been recognized by clinical trials as potentially influencing the course of OA beneficially. These include chondroitin sulfate (CS), [4][5][6][7] glucosamine, [8][9][10] diacerein, 11) doxycycline (an antibiotic belonging to the tetracycline family), 12) cyclooxygenase/5-lipoxygenase inhibitors, 13) and intra-articular injections of hyaluronic acid (HA). These approaches, however, have frequently produced insufficient benefit and excess risk of adverse effects.…”

“…[25][26][27] Furthermore, the clinical efficacy of CS has been shown in improving OA joint function and in reducing cartilage destruction. [4][5][6][7][28][29][30] Singh et al recently conducted a review of randomized trials of OA interventions in the Cochrane Database of Systemic Reviews and concluded that CS may improve pain, that it probably improves QOL, and that it probably slows down narrowing of the joint space in patients with knee OA. 31) However, there have also been reports showing no effects of CS on pain or cartilage structure.…”

The place of chondroprotectors in the treatment of osteoarthritis of the spine

“…ХС и глюкозамин с позиций доказательной медицины среди хондропротекторных средств имеют высшую сте-пень доказательности и достоверности результатов -категорию А, в связи с чем на их основе сегодня и произ-водят большинство хондропротекторов, применяющихся в мировой практике [23][24][25][26][27][28]. Поэтому применение глюко-замина и хондроитина сульфата является патогенетиче-ски обоснованным.…”

Anti-inflammatory and anti-hyperuricemia properties of chicken feet cartilage: treatment on gouty arthritis animal model

“…Hyperuricemia leads to urate crystal formation and deposition in the joints thus initiating inflammatory response by triggering proinflammatory mediator production, such as reactive oxygen species (ROS), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) (Ferrari et al, 2016;Inokuchi et al, 2008;Choi et al, 2005). Medication prescribed to treat gout includes urate lowering agents and nonsteroidal anti-inflammatory drugs (NSAIDs) but these agents are associated with intolerances or adverse effects (Busso and So, 2010;Khanna et al, 2012;Liu-Bryan and Lioté, 2005;Umamaheswari et al, 2009;Wang et al, 2008;Wortman et al, 2010). Thus, the development of novel natural agents with therapeutic potential against gout would provide great clinical significance.…”

“…The use of these compounds have become increasingly popular for treatment of arthritis as both are safe and have no adverse effect (Uebelhart et al, 2004;Lovu et al, 2008;Volpi, 2009;Nagaoka, 2014). In our previous research, CS and glucosamine had been succesfully extracted from chicken feet cartilage using aqueous method.…”